What’s New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred are listed below:

Retreatment of Persons in Whom Prior Therapy Failed:

  • The entire section was simplified with removal of less relevant sections such as treatment of interferon experienced patients.
  • Focus was changed from a genotype-based approach to retreatment based on prior regimen failure. This change is in line with changes in other areas of the guidance where reliance on genotyping has been minimized or removed.
  • A new section for re-treatment of multiple DAA regimen failures, including failure of sofobuvir/velpatasvir/voxilaprevir or sofosbuvir pluse glecaprevir/pibrentasvir was added.
  • Supporting data and references were updated throughout; including one rating strength change based on an additional prospective, randomized study of retreatment with G/P for 16 weeks.
Friday, March 12, 2021